Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Tom van den Ende, Nicolien C. de Clercq, Mark I. van Berge Henegouwen, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 12, pp. 3351-3359
Open Access | Times Cited: 211

Showing 1-25 of 211 citing articles:

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu, Yang Yang, Zhichao Liu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004291-e004291
Open Access | Times Cited: 170
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
Xiaolong Yan, Hongtao Duan, Yunfeng Ni, et al.
International Journal of Surgery (2022) Vol. 103, pp. 106680-106680
Closed Access | Times Cited: 138
Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma
Nan Zhang, Hao Zhang, Wantao Wu, et al.
Theranostics (2022) Vol. 12, Iss. 13, pp. 5931-5948
Open Access | Times Cited: 83
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
Szonja Anna Kovács, János Tibor Fekete, Balázs Győrffy
Acta Pharmacologica Sinica (2023) Vol. 44, Iss. 9, pp. 1879-1889
Open Access | Times Cited: 79
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Wenwu He, Xuefeng Leng, Tianqin Mao, et al.
The Oncologist (2022) Vol. 27, Iss. 1, pp. e18-e28
Open Access | Times Cited: 71
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer
Fan Ge, Zhenyu Huo, Xiuyu Cai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2239778-e2239778
Open Access | Times Cited: 70
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
Yujia Zhu, Jing Wen, Qiaoqiao Li, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. 371-382
Closed Access | Times Cited: 49
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Jun Yin, Jingnan Yuan, Yunjin Li, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2068-2078
Open Access | Times Cited: 43
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J. Kelly, Blair V. Landon, Ali H. Zaidi, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1023-1034
Open Access | Times Cited: 32
Purine metabolism in lung adenocarcinoma: A single‐cell analysis revealing prognostic and immunotherapeutic insights
Pengpeng Zhang, Shengbin Pei, Guangyao Zhou, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 8
Open Access | Times Cited: 23
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma
Hao Zhang, Nan Zhang, Wantao Wu, et al.
Briefings in Bioinformatics (2022) Vol. 23, Iss. 6
Closed Access | Times Cited: 67
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Zhaoqing Tang, Yan Wang, Dan Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 63
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
Wenqun Xing, Lingdi Zhao, Zheng Yan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis
Zhaoyang Wang, Changjian Shao, Yuanyong Wang, et al.
International Journal of Surgery (2022) Vol. 104, pp. 106767-106767
Closed Access | Times Cited: 60
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Mojun Zhu, Chunhua Chen, Nathan R. Foster, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 14, pp. 3021-3031
Open Access | Times Cited: 52
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Yacine Barèche, Deirdre Kelly, Farnoosh Abbas‐Aghababazadeh, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1304-1317
Closed Access | Times Cited: 47
Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review
Szonja Anna Kovács, Balázs Győrffy
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 45
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
Liu Y, Nancy G. Azizian, Delaney K. Sullivan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 38
An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms
Nan Zhang, Hao Zhang, Zaoqu Liu, et al.
Cell Proliferation (2023) Vol. 56, Iss. 4
Open Access | Times Cited: 35
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
Dashan Ai, Shengnan Hao, Wenbin Shen, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102471-102471
Open Access | Times Cited: 14
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Amy J. Wisdom, Christopher A. Barker, Joe Y. Chang, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 118, Iss. 5, pp. 1404-1421
Closed Access | Times Cited: 13
Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
Xin Xu, Zhiyong Sun, Qiang Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008631-e008631
Open Access | Times Cited: 12
Deciphering lung adenocarcinoma evolution: Integrative single‐cell genomics identifies the prognostic lung progression associated signature
Pengpeng Zhang, Zijun Yang, Liu Zuo, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 11
Open Access | Times Cited: 11
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
Ning Jiang, Jingyuan Zhang, Zhen Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008229-e008229
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top